Ann: BARD1 Autoantibody Test Results for Ovarian Cancer Published, page-50

As you also seem to read announcements carefully, you overlooked those 3 announcements that cited concerning the transfer of the BARD1 autoantibody test from the MSD platform onto the Luminex platform, of which we were informed that it is suitable for use in a commercial test. My understanding of the faulty information of this company is that it does not understand what it is doing, it just collects different projects from universities. It seems there is nobody (at least I cannot find that in their description) in the company who understands what they are doing. I compare to other Australian companies that have experts in their field in the company not outsourced, e.g. IMM, GTG, not to speak of the US with CRIP etc. BD1 website and announcements sound like written by complete amateurs. I believe it will further dilute its competence and SP.